Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viridian Therapeutics
Biotech
Kissei pays Viridian $70M to challenge Amgen for Japanese market
Kissei is paying $70 million upfront for Japanese rights to two thyroid eye disease assets, establishing the company as a potential rival to Amgen.
Nick Paul Taylor
Jul 30, 2025 4:50am
Private equity firms take over bluebird's nest—Chutes & Ladders
Feb 28, 2025 8:30am
Viridian eye disease phase 3 hits, advancing push to rival Amgen
Sep 10, 2024 8:10am
Longtime BioMarin CEO hands off baton—Chutes & Ladders
Nov 3, 2023 9:30am
Viridian looks to beat Horizon's Tepezza in thyroid eye disease
Jul 10, 2023 4:01pm
